Nectar Lifescience Ltd (NECLIFE) is currently trading at 10.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Nectar Lifesciences Limited is an integrated pharmaceutical manufacturer focused historically on cephalosporin Active Pharmaceutical Ingredients (APIs), sterile APIs and phytochemicals, with multiple manufacturing units and a stated global leadership position in several cephalosporin APIs such as Cefixime Trihydrate and Cefuroxime Axetil. In mid-2025 Nectar executed a transformational divestment: a Business Transfer Agreement and Asset Purchase Agreement with Ceph Lifesciences Private Limited that completed November 10, 2025 for approximately INR 127,398.55 lakhs, transferring the Pharma and menthol/menthol-assets and reclassifying those operations as discontinued per Ind AS 105. The interim financials show the divested Pharma business produced very large discontinued-period losses and working capital balances; consolidated results record profit before tax from discontinued operations of negative INR 27,001.61 lakhs for the quarter and negative INR 36,572.44 lakhs for the half year, reflecting the P&L and balance-sheet impact of the divestment and related adjustments. Post-transaction, Nectar’s continuing operations are materially smaller: standalone revenue from continuing operations was approximately INR 499.66 lakhs for the quarter ended September 30, 2025, while continuing operations reported modest losses; the company retains large cash balances and receivables but faces a redefined operating focus and capital allocation decision following the divestment.

Over the past 52 weeks, Nectar Lifescience Ltd has traded between a low of ₹9.20 and a high of ₹22.49. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Nectar Lifescience Ltd has a market capitalization of approximately 200.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Nectar Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.96 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 200.67 Cr, Nectar Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Nectar Lifescience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Nectar Lifescience Ltd is 13.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The AGM is scheduled for September 18, 2026, and the book closure is from September 12, 2026 to September 18, 2026 (both days inclusive).